Loading patent…
AssigneeLigand Pharmaceuticals Incorporated
InventorsIan Peter Lamb, H. Martin Seidel
Estimating the term…
The present invention provides oligonucleotide sequences comprising DNA regulatory elements comprising point mutations of Ly6E GAS element that bind activated transcriptional regulatory proteins in response to signaling molecules, such as cytokines. Further, the present invention also provides DNA constructs comprising the oligonucleotide sequences, cells transfected with the DNA constructs, and methods of using the DNA constructs and transfected cells to provide for the controlled expression of structural genes, for the detection and recovery of transcriptional regulatory proteins, and for measuring the ability of compounds to act as agonist and antagonists of gene transcription.
An isolated DNA molecule 13 to 200 nucleotides in length comprising at least one regulatory element that binds to an activated transcriptional regulatory protein, said regulatory element comprising a nucleotide sequence of TATTCCTGGAAGT (SEQ ID No. 1), TATTCCGGTAAGT (SEQ ID No. 2), TCTTCCTGTAAGT (SEQ ID No. 3), TATTCCCGTAAGT (SEQ ID NO. 6), or TATTCCTATAAGT (SEQ ID No. 7).
A DNA construct comprising a heterologous gene that comprises at least one regulatory element and a promoter operably linked to a structural gene, wherein said structural gene is under the transcriptional control of the regulatory element and promoter, said regulatory element comprising a nucleotide sequence of TATTCCTGGAAGT (SEQ ID No. 1), TATTCCGGTAAGT (SEQ ID No. 2), TCTTCCTGTAAGT (SEQ ID No. 3), TATTCCCGTAAGT (SEQ ID NO. 6), or TATTCCTATAAGT (SEQ IDS No. 7).
An isolated DNA molecule 13 to 200 nucleotides in length comprising at least one regulatory element, said regulatory element comprising a nucleotide sequence of TATTCCTGGAAGT (SEQ ID No. 1), TATTCCGGTAAGT (SEQ ID No. 2), TCTTCCTGTAAGT (SEQ ID No. 3), TATTCCCGTAAGT (SEQ ID NO. 6), or TATTCCTATAAGT (SEQ ID No. 7), or a complement thereof.
Dependencies are inferred from the claim text.